HLS Therapeutics Inc Share Price Toronto S.E.
Equities
AM
CA05328X1015
Pharmaceuticals
Sales 2024 * | 64.08M 87.58M 5.13B | Sales 2025 * | 73.43M 100M 5.88B | Capitalization | 108M 148M 8.67B |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.34M -1.6B | Net income 2025 * | -17M -23.24M -1.36B | EV / Sales 2024 * | 1.69 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.47 x |
P/E ratio 2024 * |
-6.33
x | P/E ratio 2025 * |
-9.44
x | Employees | - |
Yield 2024 * |
4.36% | Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on HLS Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 30/04/23 |
John Hanna
DFI | Director of Finance/CFO | - | 21/06/23 |
Ryan Lennox
CMP | Compliance Officer | 43 | 06/05/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 17/06/21 |
Laura Brege
BRD | Director/Board Member | 66 | 20/03/19 |
John Hanna
DFI | Director of Finance/CFO | - | 21/06/23 |
1st Jan change | Capi. | |
---|---|---|
+17.35% | 71.39B | |
+2.39% | 25.1B | |
+5.38% | 8.59B | |
+6.69% | 8.19B | |
-20.96% | 7.91B | |
+0.49% | 4.54B | |
+17.12% | 4.31B | |
-3.38% | 3.93B | |
-2.61% | 3.86B |